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A B S T R A C T
Here, we report that the modification of liposome surfaces with AG73 peptides enhances
delivery of the lipophilic anticancer drug, edelfosine, to tumor cells overexpressing the cell-
surface receptor, syndecan 2.To test the effect of liposomal surface density of AG73 peptides
on cellular uptake, we synthesized AG73 peptide-conjugated polyethylene glycol (MW 2000)
lipid and incorporated it into fluorescence dye-labeled anionic liposomes with different ligand
densities (1, 2, or 5 mol% of total lipids). Cellular uptake of AG73-peptide–modified lipo-
somes gradually increased in proportion to the surface ligand density. The percentages of
cells positive forAG73-modified, fluorescent-dye–labeled liposomeswere 19.8 ± 2.0%, 23.1 ± 5.0%,
and 99.2 ± 1.0%, for ligand mole percentages of 1, 2, and 5, respectively. The cell-targeting
ability of AG73-modified liposomes was not significantly altered by the serum content of
culture media. In keeping with the observed enhanced cellular uptake, AG73-peptide–
modified liposomes entrapping edelfosine exhibited greater cancer cell-killing effects compared
with unmodified liposomes. Following intravenous administration into tumor-bearing mice,
AG73-peptide–modified liposomes showed 2.1-fold greater accumulation in tumors than un-
modified liposomes. These results support the feasibility of using syndecan 2–directed
liposomes for delivery of edelfosine.
© 2016 Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical










Edelfosine, an alkylphospholipid analog anticancer agent, is
known to induce apoptosis of cells in solid tumor through an
endoplasmic reticulum stress response and interaction with
mitochondria [1,2]. Although edelfosine has shown promis-
ing anticancer effects, the dose-dependent hemolysis of
edelfosine and its toxicity toward normal tissues such as bone
marrow cells [3] have limited its further use in clinical appli-
cations. Thus, tumor-targeted delivery would be helpful for
reducing the side effects of edelfosine to normal tissues.
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Although previous studies have described nanoparticle for-
mulations of edelfosine that reduce toxicity [4,5], there has been
little effort to formulate edelfosine in surface-modified lipo-
somes with appropriate tumor-cell–targeting ligands.
Syndecans are transmembrane heparan sulfate
proteoglycans that act as cell surface receptors for a variety
of proteins, including growth factors [6], enzymes [7] and
extracellular matrix proteins [8,9]. Recent studies have dem-
onstrated that syndecans are overexpressed in malignant cells
[7,10], where they promote cell adhesion, proliferation [7], and
invasion [11]. The receptor, syndecan 2, is considered a prog-
nostic marker of various malignant cells, including those of
pancreatic adenocarcinomas [12], oral squamous cell carcino-
mas [13], and colon carcinomas [14]. It is known to be up-
regulated on the surface of cancer cells [10,15] and has been
shown to play an important role in the progression of breast
carcinoma [11,16].
Here, we tested the syndecan 2–targeting ability of peptide-
ligand–modified liposomes for tumor-cell–targeted delivery of
edelfosine. We demonstrated that syndecan 2–targeting lipo-
somes with 5 mol% density of ligand enhanced the cellular
delivery, tumor accumulation, and therapeutic effects of
edelfosine.
2. Materials and methods
2.1. Synthesis of lipids tagged with a syndecan 2 ligand
The peptide sequence of the syndecan 2 ligand, AG73, is
CGGRKRLQVQSIRT (Peptron Inc., Daejeon, South Korea). In this
sequence, the two glycines and a cysteine act as a spacer and
an attachment site for maleimide-functionalized lipids, re-
spectively. AG73 peptide (11 μmol) was dissolved in 10 ml of
dimethyl sulfoxide (DMSO), to which dithiothreitol (Sigma-
Aldrich, St. Louis, MO, USA) was subsequently added at a final
concentration of 1 mM.After adding 10 μmol of 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-
[maleimide(polyethylene glycol)2000] (ammonium salt) (Avanti
Lipids, Birmingham, AL, USA) dissolved in 10 ml of DMSO, the
reaction mixture was stirred at 4 °C for 24 h, then dialyzed
(MWCO 2000 Da; Spectrum Laboratories, Inc., Rancho Domin-
guez, CA, USA) against 25% ethanol for 12 h and against
deionized water for 24 h. The resulting product was con-
firmed by 1H NMR analysis.
2.2. Preparation of liposomes
Liposomes were prepared as described previously [17] with slight
modification. For preparation of liposomes, 2 μmol each of egg
L-α-phosphatidylcholine (Avanti Lipids), egg L-α-phosphatidyl-
DL-glycerol (Avanti Lipids), cholesterol (Sigma-Aldrich), and 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N [methoxy
(polyethylene glycol)2000] (PEG2K-DSPE; Avanti Lipids) or AG73-
PEG2K-DSPE were mixed at a molar ratio of 2:2:2:0.3 in
organic solvents. In some experiments, fluorescent lipo-
somes were prepared by adding 0.2 μmol of 18:1–12:0 Square-
685 phosphatidylcholine (Avanti Polar Lipids) or N-(7-nitrobenz-
2-oxa-1,3-diazol-4-yl)-1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine (triethylammonium salt) (NBD-PE;
Molecular Probes, Inc., Eugene, OR, USA) to the previously de-
scribed lipid mixtures. Liposomes loaded with edelfosine (Tocris
Bioscience, Bristol, UK) were prepared by adding 2 μmol of
edelfosine to the previously described lipid mixtures. For com-
parison with edelfosine-loaded liposomes, 1-stearoyl-2-hydroxy-
sn-glycero-3-phosphocholine (Lyso PC; Avanti Polar Lipids)-
loaded liposomes were prepared by substituting 2 μmol of Lyso
PC for edelfosine. Organic solvents were removed from lipid
mixtures using a rotary evaporator.The resulting thin films were
hydrated with 1 ml of HEPES-buffered saline (pH 7.4) and
vortexed. The resulting multilamellar vesicles were extruded
three times through 0.2-μm polycarbonate membrane filters
(Millipore Corp., Billerica, MA, USA) and then incubated at 4 °C
before use.
2.3. Syndecan 2 expression on cancer cell surfaces
Flow cytometry was used to evaluate the expression of
syndecan 2 on the cell surface.After harvesting, BT20 cells were
incubated for 1 h at 4 °C in cold phosphate-buffered saline (PBS)
containing 3% bovine serum albumin. Next, cells were washed
and incubated for 1 h at 4 °C with an allophycocyanin-
conjugated rat anti-human syndecan 2 monoclonal antibody
(R&D Systems, Inc., Minneapolis, MN, USA), diluted 1:50 in cold
PBS containing 2% fetal bovine serum (FBS). Antibody-stained
cells were then analyzed by flow cytometry using a BD
FACSCalibur system equipped with Cell Quest Pro software (BD
Bioscience, San Jose, CA, USA).
2.4. Cellular uptake
Cellular uptake of liposomes containing NBD-PE was as-
sessed using fluorescence microscopy and flow cytometry. For
fluorescence microscopy, BT20 cells were seeded onto
24-well plates at a density of 5 × 104 cells/well. In some ex-
periments, the medium was replaced with medium containing
different concentrations of FBS (10%, 20%, or 50%) or with 100%
FBS. After 24 h, cells were treated with 20 μl of fluorescent li-
posomes for 30 min, then washed twice with PBS and observed
under a fluorescence microscope (Leica DM IL; Leica,Wetzlar,
Germany). Fluorescent-liposome–treated cells were har-
vested, washed three times with cold PBS containing 2% FBS,
and analyzed by flow cytometry.
2.5. Animals
Five-week-old female Balb/c athymic nude mice, obtained from
Orient Bio. Inc. (Seungnam, Kyonggi-do, South Korea; ap-
proved animal experimental protocol number SNU-150609-
2), were used for in vivo experiments.Animals were raised under
standard pathogen-free conditions at the Animal Center for
Pharmaceutical Research, Seoul National University. All animal
experiments were conducted in accordance with the Guide-
lines for the Care and Use of Laboratory Animals of the Institute
of Laboratory Animal Resources, Seoul National University.
2.6. Anticancer activity
The anticancer activity of liposomes containing edelfosine or
Lyso PC was tested using a Cell Counting Kit (CCK) assay. BT20
597a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 1 ( 2 0 1 6 ) 5 9 6 – 6 0 2
cells were seeded onto a 48-well plate at a density of 2 × 104
cells per well, and treated with liposomes containing 5 nM
edelfosine or Lyso PC. After 24 h, cell viability was quantified
using a CCK according to the protocol provided by the manu-
facturer (Dojindo Molecular Technologies, Inc., Rockville, MD,
USA). Cell viability was expressed as a percentage of that mea-
sured in control groups.
2.7. In vivo molecular imaging
Molecular imaging was used to trace the distribution of PEG-
and AG73-PEG–modified liposomes (PEG2KLipo and AG73-
PEG2KLipo, respectively). Mice were subcutaneously inoculated
in the dorsal right side with 4 × 106 BT20 cells. After tumors
had grown to approximately 100–150 mm3, 200 μl of Square-
685 lipid-loaded fluorescent liposomes were intravenously
injected.At 2 h post-dose, Square-685 fluorescence was imaged
using an eXplore Optix system (Advanced Research Technolo-
gies Inc., Montreal, Canada). A 670-nm pulsed-laser diode was
used to excite Square-685 molecules.
2.8. Statistics
Analysis of variance (ANOVA) with post hoc Student–Newman–
Keuls test was used for statistical evaluation of experimental
data. All statistical analyses were done using SigmaStat soft-
ware (version 3.5; Systat Software, Richmond, CA, USA). A
P-value <0.05 was considered statistically significant.
3. Results and discussion
3.1. Construction of AG73-PEG2KLipo for syndecan
2 targeting
The premise of these studies is that syndecan 2 overexpressing
cancer cells can be targeted byAG73-PEG2KLipo through receptor-
mediated cellular delivery, as shown in Fig. 1. To this end, we
grafted the AG73 peptide, utilized as a ligand for the receptor,
syndecan 2, onto liposomes as described in section 2; lipo-
somes prepared without AG73 (PEG2KLipo) were used as controls.
There was no significant difference in particle sizes (Fig. 2A)
or zeta potentials (Fig. 2B) between liposomes. AG73 is a bio-
logically active peptide originating from the cell-adhesion
protein laminin α1 [18,19] that is known to promote cell at-
tachment [20], angiogenesis [21], tumor growth, and metastasis
[22] in various malignant cells through binding to syndecans.
Yamada and colleagues [23] have utilized AG73 as a cell-
adhesion ligand to modify hyaluronic acid hydrogels for tissue
engineering, and Negishi and colleagues [24] have used ultra-
sound imaging of AG73-modified bubble liposomes for tumor
diagnosis.
3.2. Cellular delivery of AG73-PEG2KLipo with various
densities of ligand
AG73 peptide tagging affected the efficiency of cellular uptake
of liposomes in syndecan 2–expressing cancer cells. Surface
expression of syndecan 2 on BT20 cancer cells was con-
firmed by flow cytometry (Fig. 3A). BT20 cells treated with AG73-
PEG2KLipo, labeled with the fluorescent dye, NBD-PE, to allow
fluorescence monitoring, showed a gradual increase in cellu-
lar uptake efficiency as a function of AG73 content on the
liposome surface (Fig. 3E,F,G), whereas PEG2KLipo was not taken
up by cells regardless of PEG2K content (Fig. 3B,C,D). AG73-
PEG2KLipo modified with 5 mol% of added ligand achieved the
greatest cellular delivery (Figs. 3 and 4), with 99.2 ± 1.0% of cells
treated with this preparation exhibiting fluorescence (Fig. 4C,D)
compared with 19.8 ± 2.0% and 23.1 ± 5.0% of cells prepared with
1mol% (Fig. 4A,D) and 2mol% (Fig. 4B,D) of ligand. Ligandmodi-
fication of PEGylated nanoparticles has been suggested as an
effective solution to the so-called “PEG dilemma” [25], which
reflects inhibition of cellular uptake of nanoparticles by the PEG
stabilizer. As an example of the latter effect, PEGylated
nanoparticles with 5 mol% PEG achieved a significantly higher
concentration in blood, but lower cellular delivery of cargo, than
PEG-unmodified nanoparticles after systemic injection [26].The
AG73 ligand modification was able to reverse the effects of PEG
on cellular delivery. This ability of AG73 modification to effec-
tively overcome the PEG dilemma is important because
PEGylation serves valuable functions, providing a hydro-
philic, flexible spacer between ligand molecules and liposomes
to improve functionality of the ligand and protecting lipo-
somes from interaction with biological fluids [27].
Fig. 1 – AG73-modified liposomes for syndecan 2 targeting
of edelfosine. AG73-PEG2KLipo for targeting edelfosine to
syndecan 2 on cancer cells is depicted.
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3.3. Cellular delivery of AG73-PEG2KLipo in
biological fluids
The cellular-uptake efficiency of AG73-PEG2KLipo was not in-
fluenced by serum-containing conditions that mimic biological
fluids (Fig. 5). Likewise, the cancer cell-targeting ability of AG73-
PEG2KLipo was similarly unaffected by increased serum
conditions. Only the 100% serum condition slightly decreased
cellular uptake of AG73-PEG2KLipo (to 82.5% ± 5.0%). On the basis
of these results, AG73 modification would not be expected to
alter the pharmacokinetic profile of PEG2KLipo. Indeed, several
groups have reported that modification of liposomes with
ligands targeting epithelial cell adhesion molecule [28], epi-
dermal growth factor receptor [29], or Her2/neu [30] did not
increase clearance of liposomes, but did increase tumor ac-
cumulation compared with unmodified liposomes.
3.4. Antitumor effect of edelfosine delivered by
AG73-PEG2KLipo
Edelfosine-encapsulated AG73-PEG2KLipo showed enhanced
cancer cell-killing effects (Fig. 6). CCK assays revealed that treat-
ment with edelfosine-loaded liposomes with a PEG2K or AG73-
PEG2K content of 1 or 2 mol% had no significant effect on BT20
cell viability. In contrast, treatment with edelfosine-loaded li-
posomes containing 5 mol% PEG2K or AG73-PEG2K content
exerted tumor cell-killing effects, reducing cell viability to
64.2% ± 2.5% and 46.1% ± 9.2%, respectively. Edelfosine acts as
an anticancer agent by inducing apoptosis in malignant cells,
including breast cell carcinoma [3,31]. However, severe side
effects of edelfosine have been observed after systemic ad-
ministration [32]. Recent reports have reported that edelfosine
can be formulated into lipid bilayers of liposomes owing to its
lipid-like structure [5,33,34]. Liposomal edelfosine formula-
tions have been shown to prevent against the toxicity of free
edelfosine, demonstratingmuch higher safety than the free drug
[5] and an improved therapeutic index as a result of their en-
hanced toxicity toward resting cancer cells [34].
3.5. Tumor accumulation of AG73-PEG2KLipo
Systemically injected AG73-PEG2KLipo nanoparticles with a
5 mol% AG73-PEG2K content were mainly distributed to tumor
tissues of mice xenografted with syndecan 2–overexpressing
BT20 cells (Fig. 7A).The fluorescence intensity in tumor regions
Fig. 2 – Characterization of AG73-PEG2KLipo. (A) Particle
sizes of PEG2KLipo and AG73-PEG2KLipo were measured by
dynamic light scattering. (B) Zeta potentials were
determined using an electro-Doppler method.
Fig. 3 – Syndecan 2–mediated cellular uptake of AG73-
PEG2KLipo. (A) The surface expression of syndecan 2 on
BT20 cell surfaces was analyzed by flow cytometry. BT20
cells were treated with NBD-PE–loaded PEG2KLipo (B,C,D) or
AG73-PEG2KLipo (E,F,G) constructed to contain 1 mol% (B,E),
2 mol% (C,F), or 5 mol% (D,G) PEG2K or AG73-PEG2K-DSPE.
After 30 min, cells were observed under a fluorescence
microscope. Scale bar, 100 μm.
599a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 1 ( 2 0 1 6 ) 5 9 6 – 6 0 2
of AG73-PEG2KLipo–treated mice was 2.1-fold higher than that
of PEG2KLipo–treated mice (Fig. 7B). PEG2KLipo, lacking the AG73
ligand, also showed some distribution to tumor sites. Such
distribution to tumors in the absence of a targeting ligand fre-
quently occurs with nanoparticulate delivery systems owing
to the enhanced retention and permeability effect [35]. However,
tumor-targeting ligands are still needed for improved intra-
cellular delivery to tumor cells [36]. Indeed, whereas PEG2KLipo-
treated mice showed higher distributions to organs other than
tumor tissue, AG73-PEG2KLipo nanoparticles were mainly dis-
tributed in tumor tissue (Fig. 7).
4. Conclusions
We synthesized AG73-peptide–conjugated PEG-lipid and for-
mulated AG73-grafted liposomes.AG73-PEG2KLipo nanoparticles
exhibited ligand density-dependent, enhanced cellular deliv-
ery in syndecan 2–overexpressing cancer cells in vitro, and
showed higher tumor accumulation than ligand-unmodified
liposomes after systemic administration in vivo. In addition,
edelfosine-loaded liposomes significantly decreased tumor cell
viability. These results provide evidence that AG73-PEG2KLipo
could serve as a receptor-specific nanovehicle for delivery of
edelfosine to syndecan 2–overexpressing cancer cells.
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Fig. 4 – Dependence of cancer cell-targeting efficiency on
the AG73-PEG2K content of liposomes. BT20 cells were
treated with NBD-PE–loaded PEG2KLipo or AG73-PEG2KLipo
constructed to contain 1 mol% (A), 2 mol% (B), or 5 mol% (C)
of PEG2K or AG73-PEG2K-DSPE. After 30 min, fluorescence-
positive populations of cells were analyzed (A–C) and
quantified (D) by flow cytometry. *P < 0.05 vs. other groups
(ANOVA and Student–Newman–Keuls test).
Fig. 5 – Effect of serum content on cellular-uptake efficiency
of AG73-PEG2KLipo. BT20 cells cultured with different
percentages of serum were treated with NBD-PE–loaded
AG73-PEG2KLipo. After 30 min, fluorescence-positive
populations of cells were analyzed by flow cytometry.
Fig. 6 – In vitro anticancer effect of edelfosine delivered by
AG73-PEG2KLipo. BT20 cells were treated with edelfosine
(50 μM)-encapsulated PEG2KLipo or AG73-PEG2KLipo. After
24 h, BT20 cell viability was measured using CCK assays
(n = 4).
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